This trial is evaluating whether ATV will improve 3 primary outcomes and 13 secondary outcomes in patients with HIV Infections. Measurement will happen over the course of Week 24.
This trial requires 100 total participants across 4 different treatment groups
This trial involves 4 different treatments. ATV is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.
"Sexual intercourse without use of HIV-prevention methods is the single most important risk factor for HIV in men. As condoms protect against some sexually transmitted diseases they also protect against HIV, but only about half of men on PrEP use them, and condom use may not be enough. Other strategies or combinations of strategies are needed to prevent the majority of new HIV infections in sub-Saharan Africa." - Anonymous Online Contributor
"This section covers medications approved for HIV infections. While no definitive treatment can be guaranteed, the use of ART generally improves overall health and promotes and sustains remission." - Anonymous Online Contributor
"This review of the literature suggests that there exist viable treatments for HIV infections after treatment discontinuation and is supportive, at least in principle, of the concept of HIV remission. The evidence base consists of one small trial with a possible selection bias in which only 20% of the trial subjects enrolled are eligible to be in the study. There is no high-quality evidence relating to cure. The trials also all contain significant limitations and it is possible that remission rates were overestimated or underestimated in the studies reviewed here. Clearly, more effective treatments for HIV infection are urgently needed. Although anecdotal cures may be found among select groups of patients, the current knowledge does not support claims that it can be cured or eliminated. Therefore, these conclusions must be interpreted with caution." - Anonymous Online Contributor
"There are approximately 700,000 new cases of HIV infection each year in the United States. This makes it the most common infectious disease in the United States." - Anonymous Online Contributor
"HIV infections are caused by two types of viruses, the single-stranded, positive-sense, HIV-1 and HIV-2 viruses. Many types of HIV-1 and HIV-2 can be spread to others by unprotected sexual intercourse. HIV infections may also be transmitted via blood transfusions. HIV infection is an infection or diseases caused by the infection of HIV-1 and HIV-2. The World Health Organization (WHO) estimated that the number of people infected by HIV/AIDS in 2010 was about 35 million people. The total number of people living with HIV/AIDS worldwide is about 25 million. HIV/AIDS can result in death within a year of infection." - Anonymous Online Contributor
"HIV infection can be suspected when a patient is febrile and positive for antibodies to the virus, but the symptoms are nonspecific and do not reliably implicate the virus. As a result, clinicians should be cautious about excluding other forms of febrile illness of presumed viral etiology, so they can more reliably rule out other causes of fever." - Anonymous Online Contributor
"It is unclear how the use of atv can be recommended. Whilst there is some evidence of potential benefit in patients with HIV-associated neurocognitive disorder, the quality of the currently available trials is poor, and the evidence for benefit was inconsistent and of poor quality. The studies available do not provide good data for the initiation of treatment with atv. In addition, it is difficult to draw generalisable conclusions about the safety and effects of atv in patients with HIV. Therefore, in routine clinical practice it is not yet possible to determine if there is an indication for atv therapy." - Anonymous Online Contributor
"HIV-1 strains from our patients fall into four distinct lineages of HIV-1 epidemics: subtype B/HIV-1 (95% of individuals infected with HIV-1) and subtype A/HIV-1 (4% of individuals infected with HIV-1), as well as subtypes F/HIV-1 and A/HIV-1 (4% of individuals infected with HIV-1) lineages. To the best of our knowledge, this is the first analysis documenting the genetic heterogeneity of HIV-1 infection dynamics." - Anonymous Online Contributor
"Atv appeared to be as effective as a placebo when prescribed for the treatment of HIV-associated dementia or HIV-associated dementia with psychosis. Larger studies would be desirable to confirm our findings." - Anonymous Online Contributor
"Based on the overall data available, the most commonly used assumption is that persons do get hiv infections at a median age of 19 years (with a 95% confidence interval at ages 18 and 23) in developed countries. However, it is possible that persons who are at increased risk of getting hiv do so at younger age, and that [the distribution of age of hiv infections is unimodal and skewed towards young ages] (see Figure)." - Anonymous Online Contributor
"HIV infections are common but often underrecognized. They account for more morbidity, mortality and costs than previously thought, so prompt diagnosis, treatment and the promotion of timely CD4 monitoring is paramount to improving outcomes. Effective use of standard care is essential in reducing morbidity and mortality and in increasing the chance of achieving a successful HIV outcome." - Anonymous Online Contributor
"It seems that the treatments that were used in the past are becoming less effective or ineffective because the virus tends to become resistant more and more fast. Since HIV and its virus have been known for more than 20 years, it is time to [find out a better way to treat HIV infections; in other words, the [new HIV treatments]] that will be effective or most effective and [have fewer adverse effects]." - Anonymous Online Contributor